Daniel Fowler

Company: Rapa Therapeutics

Job title: Chief Medical Officer

Seminars:

Clinical Translation of Hybrid Treg/Th2 (RAPA501) Cells for Therapy of ALS 2:30 pm

Mechanism of action of RAPA501 Phase 1 results; manufacturing, safety and immune modulation Implementing 40 patient Expanded Access trial (<50% pulmonary function) Implementing Phase 2/3 trial (>70% pulmonary function)Read more

day: Conference Day One Track B PM